Bolt Biotherapeutics (BOLT) Expected to Announce Earnings on Wednesday

Bolt Biotherapeutics (NASDAQ:BOLT) will likely be issuing its Q4 2025 results before the market opens on Wednesday, April 1st. Analysts expect the company to announce earnings of ($4.27) per share and revenue of $0.6670 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 12, 2026 at 7:00 AM ET.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its quarterly earnings results on Thursday, March 12th. The company reported ($3.84) earnings per share for the quarter, beating the consensus estimate of ($4.27) by $0.43. The business had revenue of $2.50 million during the quarter, compared to analysts’ expectations of $0.67 million. Bolt Biotherapeutics had a negative net margin of 433.74% and a negative return on equity of 92.54%. On average, analysts expect Bolt Biotherapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Bolt Biotherapeutics Stock Performance

Shares of NASDAQ:BOLT opened at $4.25 on Tuesday. The company has a current ratio of 3.59, a quick ratio of 3.59 and a debt-to-equity ratio of 0.76. The company has a 50-day moving average price of $5.04 and a 200-day moving average price of $5.31. The company has a market cap of $8.16 million, a price-to-earnings ratio of -0.24 and a beta of 0.95. Bolt Biotherapeutics has a 12 month low of $3.91 and a 12 month high of $9.25.

Analysts Set New Price Targets

BOLT has been the topic of a number of research analyst reports. HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Bolt Biotherapeutics in a report on Friday, March 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a report on Wednesday, January 21st. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $34.00.

Institutional Investors Weigh In On Bolt Biotherapeutics

A number of large investors have recently modified their holdings of BOLT. Squarepoint Ops LLC grew its holdings in Bolt Biotherapeutics by 19.8% in the third quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock worth $79,000 after purchasing an additional 2,448 shares during the period. Shay Capital LLC purchased a new position in shares of Bolt Biotherapeutics during the third quarter valued at approximately $85,000. Susquehanna International Group LLP purchased a new position in shares of Bolt Biotherapeutics during the third quarter valued at approximately $89,000. Finally, Renaissance Technologies LLC boosted its position in shares of Bolt Biotherapeutics by 92.2% in the 4th quarter. Renaissance Technologies LLC now owns 55,025 shares of the company’s stock worth $301,000 after purchasing an additional 26,400 shares in the last quarter. Institutional investors own 86.70% of the company’s stock.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.